ty027
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jun 9, 2020 (NCT04429529)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, passive
SARS-CoV-2 immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04649515 | Phase 3 | Dec 4, 2020 | Massachusetts Institute of Technology, Singapore General Hospital |
| NCT04429529 | Phase 1 | Jun 9, 2020 | Massachusetts Institute of Technology, SingHealth Investigational Medicine Unit |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Massachusetts Institute of Technology | Academic/Hospital | 2 | 2 | 2 | 2020 |
| Singapore General Hospital | Academic/Hospital | 1 | 0 | 1 | 2020 |
| SingHealth Investigational Medicine Unit | For profit | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1